177Lu-PSMA Radioligand therapy in patients with lymph node metastatic hormone-sensitive prostate cancer undergoing robot-assisted laparoscopic radical prostatectomy and extended pelvic lymph node dissection

To be determined0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年2月28日

研究概览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•-Men over 18 years of age
•-ECOG PS 0-1
•-Histologically proven adenocarcinoma of the prostate cancer of any grade and/or stage
•-Any prostate-specific antigen (PSA)-level
•-Planned to undergo radical prostatectomy (RARP) and extended pelvic lymph node dissection (ePLND)
•-A pre-operative [68Ga] or [18F] PSMA PET/CT positive for lymphogenic metastatic disease (1-3 metastases; miN1) in the surgical template
•-Deemed clinically fit for 177Lu-PSMA RLT
•-eGFR = 30 mL/min/1.73 m2
•-Hemoglobin (Hb) = 5.6 mmol/L
•-Leucocytes = 3.0 x 109/L
•-Thrombocytes = 100 x 109/l
•-Provided informed consent

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•-Previous treatment with any of the following within 6 months of inclusion:
•Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation
•-Previous PSMA-targeted radioligand therapy
•-Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 28 days prior to day of inclusion
•-Known hypersensitivity to the components of the study therapy or its analogs
•-Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy
•-Patients with signs of M1a-b-c disease on pre-operative PSMA PET/CT
•-Prior systemic hormonal therapy (ADT)

发起方

To be determined